Khetarpal SA, Zeng X, Millar JS, et al. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nat Med. 2017;23(9):1086-1094. doi:10.1038/nm.4390
Lu X, Peloso GM, Liu DJ, et al. Exome chip meta-analysis identifies novel loci and East Asian-specific coding variants that contribute to lipid levels and coronary artery disease. Nat Genet. 2017;49(12):1722-1730. doi:10.1038/ng.3978
Gelaye B, Clish CB, Denis M, et al. Metabolomics signatures associated with an oral glucose challenge in pregnant women. Diabetes Metab. 2019;45(1):39-46. doi:10.1016/j.diabet.2018.01.004
Peloso GM, Natarajan P. Insights from population-based analyses of plasma lipids across the allele frequency spectrum. Curr Opin Genet Dev. 2018;50:1-6. doi:10.1016/j.gde.2018.01.003
Brown EM, Xavier RJ. Without Adaptive Immunity, There’s a Cost to Responding STAT. Cell Metab. 2018;27(4):705-707. doi:10.1016/j.cmet.2018.03.011
Dockendorff C, Faloon PW, Pu J, et al. Benzo-fused lactams from a diversity-oriented synthesis (DOS) library as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake. Bioorg Med Chem Lett. 2015;25(10):2100-5. doi:10.1016/j.bmcl.2015.03.073
Nieland TJF, Shaw JT, Jaipuri FA, et al. Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity. Biochemistry. 2008;47(1):460-72. doi:10.1021/bi701277x
Hotamışlıgil GS. Endoplasmic reticulum stress and atherosclerosis. Nat Med. 2010;16(4):396-9. doi:10.1038/nm0410-396
Yu M, Romer KA, Nieland TJF, et al. Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity. Proc Natl Acad Sci U S A. 2011;108(30):12243-8. doi:10.1073/pnas.1109078108
Galagan JE, Minch K, Peterson M, et al. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature. 2013;499(7457):178-83. doi:10.1038/nature12337